Guard Therapeutics International AB is a pharmaceutical company, which engages in the research, development, and commercialization of medical treatment and diagnosis based on alpha-1-microglobulin. It focuses on the treatment of pre-eclampsia and acute kidney injury. The company was founded by Bo Åkerström, Tomas Jörgen Eriksson, Stefan Hansson, Gram Magnus on April 4, 2008 and is headquartered in Stockholm, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company